TY - JOUR
T1 - Random forest modelling demonstrates microglial and protein misfolding features to be key phenotypic markers in C9orf72-ALS
AU - Rifai, Olivia M.
AU - Longden, James
AU - O'Shaughnessy, Judi
AU - Sewell, Michael D.E.
AU - Pate, Judith
AU - McDade, Karina
AU - Daniels, Michael J.D.
AU - Abrahams, Sharon
AU - Chandran, Siddharthan
AU - McColl, Barry W.
AU - Sibley, Christopher R.
AU - Gregory, Jenna M.
N1 - Acknowledgments
We gratefully acknowledge Professor Tom Gillingwater for his helpful comments and support.
This work would not have been possible without the resources of the Edinburgh Brain Bank, and the people with ALS and their families who have generously donated tissue. This research was funded in part by a studentship from the Wellcome Trust (108890/Z/15/Z) to OMR and MDES, a Pathological Society and Jean Shanks foundation grant (217CHA R46564) to JMG and JO, and a Sir Henry Dale fellowship jointly funded by the Wellcome Trust and the Royal Society
(215454/Z/19/Z) to CRS.
PY - 2022/9/7
Y1 - 2022/9/7
N2 - Abstract Clinical heterogeneity observed across patients with amyotrophic lateral sclerosis (ALS) is a known complicating factor in identifying potential therapeutics, even within cohorts with the same mutation, such as C9orf72 hexanucleotide repeat expansions (HRE). Thus, further understanding of pathways underlying this heterogeneity is essential for appropriate ALS trial stratification and the meaningful assessment of clinical outcomes. It has been shown that both inflammation and protein misfolding can influence ALS pathogenesis, such as the manifestation or severity of motor or cognitive symptoms. However, there has yet to be a systematic and quantitative assessment of immunohistochemical markers to interrogate the potential relevance of these pathways in an unbiased manner. To investigate this, we extensively characterised features of commonly used glial activation and protein misfolding stains in thousands of images of post-mortem tissue from a heterogeneous cohort of deeply clinically profiled patients with a C9orf72 HRE. Using a random forest model to assess these features, we show that microglial staining features are the most accurate classifiers of disease status in our panel and that clinicopathological relationships exist between microglial activation status, TDP-43 pathology, and language dysfunction. Furthermore, we detected spatially resolved changes in FUS staining, suggesting that liquid-liquid phase shift of this aggregation-prone RNA-binding protein may be important in ALS caused by a C9orf72 HRE. Interestingly, no one feature alone significantly impacted the predictiveness of the model, indicating that the collective examination of all features, or a combination of several features, is what allows the model to be predictive. Our findings provide further support to the hypothesis of dysfunctional immune regulation and proteostasis in the pathogenesis of C9-ALS and provide a framework for digital analysis of commonly used neuropathological stains as a tool to enrich our understanding of clinicopathological relationships between and within cohorts. This article is protected by copyright. All rights reserved.
AB - Abstract Clinical heterogeneity observed across patients with amyotrophic lateral sclerosis (ALS) is a known complicating factor in identifying potential therapeutics, even within cohorts with the same mutation, such as C9orf72 hexanucleotide repeat expansions (HRE). Thus, further understanding of pathways underlying this heterogeneity is essential for appropriate ALS trial stratification and the meaningful assessment of clinical outcomes. It has been shown that both inflammation and protein misfolding can influence ALS pathogenesis, such as the manifestation or severity of motor or cognitive symptoms. However, there has yet to be a systematic and quantitative assessment of immunohistochemical markers to interrogate the potential relevance of these pathways in an unbiased manner. To investigate this, we extensively characterised features of commonly used glial activation and protein misfolding stains in thousands of images of post-mortem tissue from a heterogeneous cohort of deeply clinically profiled patients with a C9orf72 HRE. Using a random forest model to assess these features, we show that microglial staining features are the most accurate classifiers of disease status in our panel and that clinicopathological relationships exist between microglial activation status, TDP-43 pathology, and language dysfunction. Furthermore, we detected spatially resolved changes in FUS staining, suggesting that liquid-liquid phase shift of this aggregation-prone RNA-binding protein may be important in ALS caused by a C9orf72 HRE. Interestingly, no one feature alone significantly impacted the predictiveness of the model, indicating that the collective examination of all features, or a combination of several features, is what allows the model to be predictive. Our findings provide further support to the hypothesis of dysfunctional immune regulation and proteostasis in the pathogenesis of C9-ALS and provide a framework for digital analysis of commonly used neuropathological stains as a tool to enrich our understanding of clinicopathological relationships between and within cohorts. This article is protected by copyright. All rights reserved.
KW - Amyotrophic lateral sclerosis
KW - frontotemporal dementia
KW - C9orf72
KW - neuroinflammation
KW - microglia
KW - post-mortem tissue
KW - TDP-43
KW - FUS
KW - machine learning
KW - digital pathology
U2 - https://doi.org/10.1002/path.6008
DO - https://doi.org/10.1002/path.6008
M3 - Article
VL - n/a
JO - The Journal of pathology
JF - The Journal of pathology
SN - 0022-3417
IS - n/a
ER -